Redwood City, Calif.-based Nevro has received FDA approval for its Senza device, which delivers high-frequency spinal cord stimulation for treatment of chronic pain associated with diabetic neuropathy.

The company, which specializes in chronic pain treatment devices, said participants in an ongoing clinical trial of the device showed “substantial, sustained pain relief and improved health-related quality of life.”

Nevro believes the Senza device may allow some patients to discontinue long-term drug therapy and eliminate unwanted drug side effects.